<DOC>
	<DOCNO>NCT00154648</DOCNO>
	<brief_summary>This trial show diagnostic efficacy Gadovist contrast enhance magnetic resonance angiography ( CE-MRA ) artery .</brief_summary>
	<brief_title>CE-MRA Using Gadovist Comparison IA DSA Using Ultravist</brief_title>
	<detailed_description>This trial show diagnostic efficacy Gadovist contrast enhance Magnetic Resonance Angiography ( CE-MRA ) artery ( specify vessel segment ) analyze rate agreement , image quality , diagnostic confidence CE-MRA base diagnosis diagnosis achieve comparator procedure IA DSA use Ultravist .</detailed_description>
	<criteria>With suspect known disease artery Scheduled IA DSA/cut film angiography artery period le 7 day prior study period complete delineation documentation vessel . Willing able continue study participation . This include administration GadovistÂ® 1.0 completion procedure require study protocol Patient 20 75 year age Fully inform sign consent advance Patient clinically unstable his/her clinical course 72 hour safety observation period unpredictable Patient renal failure Woman pregnant childbearing potential without negative pregnancy test prior enrollment ( within 72 hour prior CEMRA ) Lactating woman Patient contraindication magnetic resonance imaging ( MRI ) examination IA DSA . Patient receive investigational drug within 30 day prior study entry plan receive investigational drug safety followup ( 72 hour CEMRA ) . Patient schedule surgery intervention within 72 hour CEMRA/IA DSA procedure within 48 hour prior study CEMRA/IA DSA . Hypersensitivity gadobutrol product Patient previously enter study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2005</verification_date>
	<keyword>MRA</keyword>
	<keyword>DSA</keyword>
	<keyword>gadovist</keyword>
	<keyword>angiography</keyword>
</DOC>